{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-25-000135","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.225638+00:00","generated_at":"2026-05-16T20:28:04.851085+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Serina Therapeutics Q3 net loss $4.6M; FDA places SER-252 on clinical hold","bullets":["Net loss of $4.6M ($0.45 per share) vs net income of $1.4M in Q3 2024.","FDA placed IND for SER-252 on clinical hold due to excipient question; not related to active drug.","Secured up to $20M convertible note/warrant financing; first $5M drawn in September 2025.","ATM program raised $2.8M net; 474,712 shares issued at avg $6.00 per share.","Cash $8.6M as of Sept 30; R&D expenses rose to $3.6M from $2.4M year-over-year."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-25-000135","json":"https://secwatch.observer/filing/0001708599-25-000135.json","markdown":"https://secwatch.observer/filing/0001708599-25-000135.md","text":"https://secwatch.observer/filing/0001708599-25-000135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000135/0001708599-25-000135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000135/ser-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:28:04.851085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}